TY  - JOUR
T1  - ALprazolam augmentation of antipsychotic pharmacotherapy?-reply
AU  - Wolkowitz OM, Breier A, Doran A, et al
Y1  - 1989/11/01
N1  - 10.1001/archpsyc.1989.01810110094014
JO  - Archives of General Psychiatry
SP  - 1052
EP  - 1053
VL  - 46
IS  - 11
N2  - In Reply.— 
    Thienhaus and colleagues have raised several issues. To clarify the issue of baseline fluphenazine administration in our study, the number of capsules (active or placebo) was the same during the period of protocol participation for each patient. Since patients were unaware of when alprazolam was substituted, the possibility of a placebo response based on a new or increased capsule number was minimal or absent.Thienhaus et al also questioned our choice of the BPRS as a measure of clinical change. While there are a number of scales that might have been appropriate in our study, the BPRS has been used effectively for over 25 Years.1 It has high discriminant validity2 and consists of clinically familiar symptoms and behavioral constructs that are suited to the level of abstraction and integration used by clinicians. Although its measure of psychopathology is somewhat global, we examined specific subscale scores (eg,
SN  - 0003-990X
M3  - doi: 10.1001/archpsyc.1989.01810110094014
UR  - http://dx.doi.org/10.1001/archpsyc.1989.01810110094014
ER  -